132 related articles for article (PubMed ID: 32211849)
21. Linc00518 Contributes to Multidrug Resistance Through Regulating the MiR-199a/MRP1 Axis in Breast Cancer.
Chang L; Hu Z; Zhou Z; Zhang H
Cell Physiol Biochem; 2018; 48(1):16-28. PubMed ID: 30001527
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
[TBL] [Abstract][Full Text] [Related]
23. SNHG22 overexpression indicates poor prognosis and induces chemotherapy resistance via the miR-2467/Gal-1 signaling pathway in epithelial ovarian carcinoma.
Zhang PF; Wu J; Luo JH; Li KS; Wang F; Huang W; Wu Y; Gao SP; Zhang XM; Zhang PN
Aging (Albany NY); 2019 Oct; 11(19):8204-8216. PubMed ID: 31581131
[TBL] [Abstract][Full Text] [Related]
24. KDM5A promotes proliferation and EMT in ovarian cancer and closely correlates with PTX resistance.
Feng T; Wang Y; Lang Y; Zhang Y
Mol Med Rep; 2017 Sep; 16(3):3573-3580. PubMed ID: 28714030
[TBL] [Abstract][Full Text] [Related]
25. MiR-181a upregulation is associated with epithelial-to-mesenchymal transition (EMT) and multidrug resistance (MDR) of ovarian cancer cells.
Li L; Xu QH; Dong YH; Li GX; Yang L; Wang LW; Li HY
Eur Rev Med Pharmacol Sci; 2016 May; 20(10):2004-10. PubMed ID: 27249598
[TBL] [Abstract][Full Text] [Related]
26. Long noncoding RNA H19 acts as a miR-340-3p sponge to promote epithelial-mesenchymal transition by regulating YWHAZ expression in paclitaxel-resistant breast cancer cells.
Yan L; Yang S; Yue CX; Wei XY; Peng W; Dong ZY; Xu HN; Chen SL; Wang WR; Chen CJ; Yang QL
Environ Toxicol; 2020 Sep; 35(9):1015-1028. PubMed ID: 32420678
[TBL] [Abstract][Full Text] [Related]
27. MiR-21-5p enhances the progression and paclitaxel resistance in drug-resistant breast cancer cell lines by targeting PDCD4.
Tao L; Wu YQ; Zhang SP
Neoplasma; 2019 Sep; 66(5):746-755. PubMed ID: 31169019
[TBL] [Abstract][Full Text] [Related]
28. Non-coding RNA LOXL1-AS1 exhibits oncogenic activity in ovarian cancer via regulation of miR-18b-5p/VMA21 axis.
Xue F; Xu YH; Shen CC; Qin ZL; Zhou HB
Biomed Pharmacother; 2020 May; 125():109568. PubMed ID: 32058209
[TBL] [Abstract][Full Text] [Related]
29. LINC01579 promotes cell proliferation by acting as a ceRNA of miR-139-5p to upregulate EIF4G2 expression in glioblastoma.
Chai Y; Xie M
J Cell Physiol; 2019 Dec; 234(12):23658-23666. PubMed ID: 31187495
[TBL] [Abstract][Full Text] [Related]
30. NF-κB1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer.
Shuang T; Wang M; Zhou Y; Shi C; Wang D
Oncotarget; 2017 Apr; 8(15):24853-24868. PubMed ID: 28206956
[TBL] [Abstract][Full Text] [Related]
31. LncRNA KB-1471A8.2 Overexpression Suppresses Cell Proliferation and Migration and Antagonizes the Paclitaxel Resistance of Ovarian Cancer Cells.
Zhang M; Liu S; Fu C; Wang X; Zhang M; Liu G; Dai C; Gong Z; Xu H; Fu Z; Xu P; Xu J; Jia X
Cancer Biother Radiopharm; 2019 Jun; 34(5):316-324. PubMed ID: 30892073
[No Abstract] [Full Text] [Related]
32. MiR-1307 influences the chemotherapeutic sensitivity in ovarian cancer cells through the regulation of the CIC transcriptional repressor.
Zhou Y; Wang M; Shuang T; Liu Y; Zhang Y; Shi C
Pathol Res Pract; 2019 Oct; 215(10):152606. PubMed ID: 31500928
[TBL] [Abstract][Full Text] [Related]
33. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
Wu D; Lu P; Mi X; Miao J
Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
[TBL] [Abstract][Full Text] [Related]
34. Reversal of paclitaxel resistance in human ovarian cancer cells with redox-responsive micelles consisting of α-tocopheryl succinate-based polyphosphoester copolymers.
Chen FQ; Zhang JM; Fang XF; Yu H; Liu YL; Li H; Wang YT; Chen MW
Acta Pharmacol Sin; 2017 Jun; 38(6):859-873. PubMed ID: 28260803
[TBL] [Abstract][Full Text] [Related]
35. Mechanisms of paclitaxel-induced apoptosis in an ovarian cancer cell line and its paclitaxel-resistant clone.
Sugimura M; Sagae S; Ishioka S; Nishioka Y; Tsukada K; Kudo R
Oncology; 2004; 66(1):53-61. PubMed ID: 15031599
[TBL] [Abstract][Full Text] [Related]
36. Gallic acid sensitizes paclitaxel-resistant human ovarian carcinoma cells through an increase in reactive oxygen species and subsequent downregulation of ERK activation.
Sánchez-Carranza JN; Díaz JF; Redondo-Horcajo M; Barasoain I; Alvarez L; Lastres P; Romero-Estrada A; Aller P; González-Maya L
Oncol Rep; 2018 Jun; 39(6):3007-3014. PubMed ID: 29693189
[TBL] [Abstract][Full Text] [Related]
37. Long noncoding RNA WDFY3-AS2 suppresses tumor progression by acting as a competing endogenous RNA of microRNA-18a in ovarian cancer.
Li W; Ma S; Bai X; Pan W; Ai L; Tan W
J Cell Physiol; 2020 Feb; 235(2):1141-1154. PubMed ID: 31347170
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA-128/homeobox B8 axis regulates ovarian cancer cell progression.
Li R; Gong L; Li P; Wang J; Bi L
Basic Clin Pharmacol Toxicol; 2019 Dec; 125(6):499-507. PubMed ID: 31271703
[TBL] [Abstract][Full Text] [Related]
39. Roles of a TMPO-AS1/microRNA-200c/TMEFF2 ceRNA network in the malignant behaviors and 5-FU resistance of ovarian cancer cells.
Li H; Zhou Y; Cheng H; Tian J; Yang S
Exp Mol Pathol; 2020 Aug; 115():104481. PubMed ID: 32497621
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1.
Wu DD; Li XS; Meng XN; Yan J; Zong ZH
Tumour Biol; 2016 Aug; 37(8):10499-506. PubMed ID: 26850595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
